CompletedPhase 4NCT00179478
Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis
Studying Acute transverse myelitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beth Israel Deaconess Medical Center
- Principal Investigator
- Revere P Kinkel, MDBeth Israel Deaconess Medical Center
- Intervention
- interferon beta 1a 30 ug IM once weekly(drug)
- Enrollment
- 155 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2001 – 2009
Study locations (26)
- MS Treatment Center at Griffin Hospital, Derby, Connecticut, United States
- Jaeb Center for Health Research, Tampa, Florida, United States
- MS Center of Atlanta, Atlanta, Georgia, United States
- Beta Research, Inc, Elk Grove, Illinois, United States
- University of Iowa College of Medicine, Iowa City, Iowa, United States
- Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
- Michigan State University, East Lansing, Michigan, United States
- St. Louis University Health Sciences Center, St Louis, Missouri, United States
- Jacobs Neurological Institute, Buffalo, New York, United States
- University of Rochester, Rochester, New York, United States
- Carolinas Medical Center - MS Center, Charlotte, North Carolina, United States
- Cleveland Clinic Foundation, Cleveland, Ohio, United States
- The Ohio State University, Columbus, Ohio, United States
- The Neurology Group, Norristown, Pennsylvania, United States
- Univeristy of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
- +11 more locations on ClinicalTrials.gov
Collaborators
Biogen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00179478 on ClinicalTrials.gov